Treatment with αIL-33 Antibody (Ab) in a Dinitrochlorobenzene (DNCB)-induced AD mouse model improved AD-like symptoms, reduced eosinophil and mast cell infiltration, and decreased serum Immunoglobulin E (IgE) levels (18). The gene discussed is IGHE; the disease is Alzheimer disease.